Plain-English translation of NCT07777471 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new approach called "Active Default" to deliver supportive care to adults 60 and older who are starting venetoclax-based therapy for acute myeloid leukemia (AML), a serious blood cancer. The medication is often given to older patients who may have other health challenges like mobility problems, nutrition issues, or memory changes that doctors don't always address consistently. This study uses a brief health assessment to identify these needs early, then prepares personalized care recommendations for the treating doctor to approve.
Older adults with blood cancer often struggle with aging-related health problems that aren't routinely screened for or addressed during cancer treatment. This trial is testing whether a structured assessment process can help doctors catch and treat these needs more reliably, improving overall quality of life for patients.
You would complete a brief health questionnaire and short in-person checks at the start of your treatment to assess walking ability, balance, strength, memory, mood, and your current medications. Based on your results, your doctor would receive pre-prepared recommendations for supportive services—such as physical therapy, nutrition support, or social work—which they can approve or decline. Over the next 90 days, you'll receive phone check-ins and repeat some of the physical and memory assessments around two months in. You may also be invited to share your thoughts about the experience in an optional interview.
AI-generated summary from trial data · Aug 24, 2026 · Not medical advice
United States